ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation
AI-Driven Enhancements in ObvioGo 2.2 Redefine Efficiency, Compliance, and Innovation in Clinical Trial ManagementÂ
ObvioGo 2.2 offers powerful new workflow and task management tools to streamline and enhance trial operations. With real-time compliance tracking and reporting, study teams can proactively identify and address adverse events (AEs), protocol deviations, and compliance risks as they arise, simplifying study management and improving overall efficiency. ObvioGo's unified platform, now integrating real-time tracking, reporting, and a centralized data repository, unlocks new and novel AI capabilities. It enables seamless integration with existing AI models and the deployment of agentic functionalities, revolutionizing clinical trial efficiency, compliance, and safety.
"ObvioGo 2.2 represents a fundamental shift in clinical trial management, setting a new standard for efficiency and innovation" said
These enhancements simplify the study manager's role by organizing tasks and data in real-time, paving the way for more efficient and effective trial management. ObvioGo 2.2 underscores ObvioHealth's commitment to innovation, positioning the company as a leader in AI-driven clinical trial solutions. With its robust capabilities, the platform meets the growing demand for efficient, scalable, and tech-enabled research solutions, delivering significant value to sponsors and advancing the future of clinical research.
About ObvioHealth
ObvioHealth is a global leader in digital clinical trial solutions, delivering smarter, faster, and more cost-effective trials through its innovative ObvioGo platform. By integrating advanced technology with patient-centric design, ObvioHealth ensures high-quality data collection and transformative outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/obviohealth-introduces-obviogo-2-2-transforming-study-management-with-ai-driven-innovation-302349730.html
SOURCE ObvioHealth
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stegra announces closing of €1.4 billion financing round
- Sungrow Releases S+ Energy Storage Multi-Scenario White Paper
- WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share